Pronóstico del paciente tratado de síndrome de Cushing

Lacroix, 2001, Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome, Endocr Rev, 22, 75 Pivonello, 2007, Cushing's syndrome: Aftermath of the cure, Arq Bras Endocrinol Metabol, 51, 1381, 10.1590/S0004-27302007000800025 Valassi, 2012, Clinical consequences of Cushing's syndrome, Pituitary, 15, 319, 10.1007/s11102-012-0394-8 Feelders, 2012, The burden of Cushing's disease: Clinical and health-related quality of life aspects, Eur J Endocrinol, 167, 311, 10.1530/EJE-11-1095 Valassi, 2011, The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics, Eur J Endocrinol, 165, 383, 10.1530/EJE-11-0272 Colao, 1999, Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure, J Clin Endocrinol Metab, 84, 2664 Barahona, 2013, Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome, J Clin Endocrinol Metab, 98, 1093, 10.1210/jc.2012-3547 Giordano, 2011, Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission, Clin Endocrinol (Oxf), 75, 354, 10.1111/j.1365-2265.2011.04055.x Geer, 2012, Body composition and cardiovascular risk markers after remission of Cushing's disease: A prospective study using whole-body MRI, J Clin Endocrinol Metab, 97, 1702, 10.1210/jc.2011-3123 Barahona, 2009, Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome, J Clin Endocrinol Metab, 94, 3365, 10.1210/jc.2009-0766 Valassi, 2012, Adipokines and cardiovascular risk in Cushing's syndrome, Neuroendocrinology, 95, 187, 10.1159/000330416 Liu, 2003, Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice, Diabetes, 52, 1409, 10.2337/diabetes.52.6.1409 Iwasaki, 2008, Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene, Mol Cell Endocrinol, 26, 10, 10.1016/j.mce.2008.01.012 Cizza, 1997, Plasma leptin levels do not change in patients with Cushing's disease shortly after correction of hypercortisolism, J Clin Endocrinol Metab, 82, 2747 Webb, 2010, Metabolic, cardiovasculars and cerebrovascular outcomes in growth-hormone deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma, J Clin Endocrinol Metab, 95, 630, 10.1210/jc.2009-0806 Höybye, 2010, Clinical Features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease, Eur J Endocrinol, 162, 677, 10.1530/EJE-09-0836 Johannsson, 2004, Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease, Clin Endocrinol (Oxf), 60, 550, 10.1111/j.1365-2265.2004.02018.x Etxabe, 1994, Morbidity and mortality in Cushing's disease: An epidemiological approach, Clin Endocrinol (Oxf), 40, 479, 10.1111/j.1365-2265.1994.tb02486.x De Leo, 2010, Cardiovascular disease in Cushing's syndrome: Heart versus vasculature, Neuroendocrinology, 92, 50, 10.1159/000318566 Yiu, 2012, Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome, Eur J Endocrinol, 166, 27, 10.1530/EJE-11-0601 Pereira, 2010, Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome, Eur J Endocrinol, 162, 331, 10.1530/EJE-09-0621 Toja, 2012, Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure, Clin Endocrinol (Oxf), 76, 332, 10.1111/j.1365-2265.2011.04206.x Faggiano, 2003, Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission, J Clin Endocrinol Metab, 88, 2527, 10.1210/jc.2002-021558 Stuijver, 2011, Incidence of venous thromboembolism in patients with Cushing's syndrome: A multicenter cohort study, J Clin Endocrinol Metab, 96, 3525, 10.1210/jc.2011-1661 Van Zanne, 2009, Hypercoagulable state in Cushing's syndrome: A systematic review, J Clin Endocrinol Metab, 94, 2743, 10.1210/jc.2009-0290 Manetti, 2010, Changes in coagulation indexes and ocurrence of venous thromboembolism in patients with Cushing's syndrome: Results from a prospective study before and after surgery, Eur J Endocrinol, 163, 783, 10.1530/EJE-10-0583 Tsagarakis, 2006, Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications, J Endocrinol Invest, 29, 471, 10.1007/BF03344133 Akaza, 2011, Clinical outcome of subclinical Cushing's syndrome after surgical and conservative treatment, Hypertens Res, 34, 1111, 10.1038/hr.2011.90 Tsuiki, 2008, Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing's syndrome, Endocr J, 55, 737, 10.1507/endocrj.K07E-177 Tauchmanovà, 2001, Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity inpatients with endogenous glucocorticoid excess due to adrenal mass, Eur J Endocrinol, 145, 241, 10.1530/eje.0.1450241 Kobayashi, 1991, Coxarthrosis secondary to ischemic necrosis of the femoral head in Cushing's disease, Rev Chir Orthop Reparatrice Appar Mot, 77, 362 Koch, 1999, Cushing's disease presenting with avascular necrosis of the hip: An orthopedic emergency, J Clin Endocrinol Metab, 84, 3010 Saeed, 2012, Avascular necrosis of femoral heads post-adrenal surgery for Cushing's syndrome: A rare presentation, Ir J Med Sci, 181, 263, 10.1007/s11845-011-0717-1 Kaltsas, 2010, Skeletal diseases in Cushing's syndrome: Osteoporosis versus arthropathy, Neuroendocrinology, 92, 60, 10.1159/000314298 Camozzi, 2010, Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome, Eur J Endocrinol, 162, 85, 10.1530/EJE-09-0800 Dovio, 2007, Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile, J Clin Endocrinol Metab, 92, 1803, 10.1210/jc.2006-2283 Malyankar, 2000, Osteoprotegerin is an a β3-induced, NF-kB-dependent survival factor for endothelian cells, J Biol Chem, 275, 20959, 10.1074/jbc.C000290200 Kristo, 2006, Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: A prospective, long-term study, Eur J Endocrinol, 154, 109, 10.1530/eje.1.02067 Barahona, 2009, Deleterious effects of glucocorticoids replacement on bone in women after long-term remission of Cushing's syndrome, J Bone Miner Res, 24, 1841, 10.1359/jbmr.090505 Di Somma, 2003, Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: A prospective study, Clin Endocrinol (Oxf), 58, 302, 10.1046/j.1365-2265.2003.01713.x Manning, 1992, Normal bone density following cure of Cushing's syndrome, Clin Endocirnol (Oxf), 36, 229, 10.1111/j.1365-2265.1992.tb01437.x Mancini, 2004, Cushing's syndrome and bone, Pituitary, 7, 243, 10.1007/s11102-005-1051-2 Faggiano, 2003, Nephrolithiasis in Cushing's disease: Prevalence, etiopathogenesis, and modification after disease cure, J Clin Endocrinol Metab, 88, 2076, 10.1210/jc.2002-021494 Faggiano, 2002, Evaluation of circulating levels and renal clearance of natural aminoacids in patients with Cushing's disease, J Endocrinol Invest, 25, 142, 10.1007/BF03343978 Loosen, 1992, Psychiatric phenomenology in Cushing's disease, Pharmacopsychiatry, 25, 192, 10.1055/s-2007-1014405 Bourdeau, 2002, Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism, J Clin Endocrinol Metab, 87, 1949 Pereira, 2010, Neuropshychiatric disorders in Cushing's syndrome, Neuroendocrinology, 92, 65, 10.1159/000314317 Resmini, 2012, Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome, J Clin Endocrinol Metab, 97, 663, 10.1210/jc.2011-2231 Starkman, 1992, Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome, Biol Psychiatry, 32, 756, 10.1016/0006-3223(92)90079-F Tiemensma, 2010, Subtle cognitive impairment in patients with long-term cure of Cushing's disease, J Clin Endocrinol Metab, 95, 1, 10.1210/jc.2009-2032 Stokes, 1995, The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression, Eur Neuropsychopharmacol, 1, 77, 10.1016/0924-977X(95)00039-R Tiemensma, 2010, Increased prevalence of psychopathology and maladaptative personality traits after long-term cure of Cushing's disease, J Clin Endocrinol Metab, 95, E129, 10.1210/jc.2010-0512 Dorn, 1997, The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism, J Clin Endocrinol Metab, 82, 912 Da Mota, 2011, Overt immune dysfunction after Cushing's syndrome remission: A consecutive case series and review of the literature, J Clin Endocrinol Metab, 96, E1670, 10.1210/jc.2011-1317 Coalo, 2000, Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease, Clin Endocrinol (Oxf), 53, 13, 10.1046/j.1365-2265.2000.01018.x Van Aken, 2005, Quality of life in patients after long-term biochemical cure of Cushing's disease, J Clin Endocrinol Metab, 90, 3279, 10.1210/jc.2004-1375 Van der Klaaw, 2008, Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas, Clin Endocrinol (Oxf), 69, 775, 10.1111/j.1365-2265.2008.03288.x Webb, 2008, Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire, Eur J Endocrinol, 158, 623, 10.1530/EJE-07-0762 Santos, 2012, Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice, Eur J Endocrinol, 167, 337, 10.1530/EJE-12-0325 Feldt-Rasmussen, 2002, Growth hormone deficiency and replacement in hypopituitary pateitns previously treated for acromegaly or Cushing's disease, Eur J Endocrinol, 146, 67, 10.1530/eje.0.1460067 Pikkarainen, 1999, The survival and well-being of patients treated for Cushing's syndrome, J Intern Med, 245, 463, 10.1046/j.1365-2796.1999.00483.x Plotz, 1952, The natural history of Cushing's disease, Am J Med, 13, 597, 10.1016/0002-9343(52)90027-2 Dekkers, 2007, Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma, J Clin Endocrinol Metab, 92, 976, 10.1210/jc.2006-2112 Clayton, 2010, Mortality in Cushing's disease, Neuroendocrinology, 92, 71, 10.1159/000315813 Graversen, 2012, Mortality in Cushing's syndrome: A systematic review and meta-analysis, Eur J Intern Med, 23, 278, 10.1016/j.ejim.2011.10.013 Hammer, 2004, Transsphenoidal microsurgery for Cushing's disease: Initial outcomes and longterm results, J Clin Endocrinol Metab, 89, 6348, 10.1210/jc.2003-032180 Clayton, 2011, Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: Audit and meta-analysis of literature, J Clin Endocrinol Metab, 96, 1, 10.1210/jc.2010-1942